GEAM: Yield of Genetic Testing in Arrhythmic Myocarditis

What this Trial Is About

Researchers are investigating arrhythmic myocarditis, a heart condition that can cause dangerous irregular heartbeats and sudden cardiac death, especially in young people. This study focuses on understanding the role of genetic testing alongside current diagnostic methods like heart biopsy and MRI. The goal is to improve diagnosis, predict risks, identify specific disease patterns linked to genetics, and develop personalized treatment strategies by combining genetic, clinical, and inflammatory information. Participants include those with and without ventricular arrhythmias, confirmed by biopsy or MRI, who are at least 10 years old. The study collects detailed genetic, clinical, and heart function data at baseline and during follow-up visits. Genetic screening will be compared between patient groups and healthy controls to find gene variants related to myocarditis. The study also explores gene activity in heart tissue to identify targets for therapy and aims to create risk models based on multiple patient factors. During the study, participants undergo heart monitoring including ECG telemonitoring, clinical assessments, and genetic testing. Researchers will track arrhythmia patterns at the start and after 12 months and analyze how genetics influence disease progression. Healthy controls without myocarditis also provide samples for comparison. The study includes follow-up evaluations to better understand arrhythmic risk and disease mechanisms over time, lasting until 2027.

GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis.